Adaptive Biotechnologies Corp (NASDAQ:ADPT) disclosed a director stock sale on March 11, 2026, when Michelle Renee Griffin sold 15,394 shares of company stock, according to a Form 4 filed with the Securities and Exchange Commission. The shares changed hands at a weighted-average price of $13.91, producing a total transaction value of $214,130.
The filing shows the sale was executed in multiple transactions with execution prices that ranged from $13.84 to $13.96. After completing the transactions, Griffin retained direct ownership of 15,625 shares of Adaptive Biotechnologies.
At the time of the disclosure, the company’s stock was trading at $13.17. InvestingPro analysis cited in the filing places ADPT above its Fair Value and lists the stock among its Most Overvalued securities on the platform. The share price has been volatile recently - the security fell 11% over the past week while remaining up 81% over the prior 12 months.
Investors seeking further valuation context are directed to the Pro Research Report referenced in the filing, which covers ADPT and more than 1,400 other U.S. equities.
Quarterly results and analyst response
Adaptive Biotechnologies also reported fourth-quarter 2025 results that outpaced analysts' expectations. The company recorded earnings per share of -$0.09, beating the forecasted -$0.18, and generated revenue of $71.7 million versus the anticipated $59.33 million.
Following the results, several research firms adjusted their price targets. TD Cowen increased its target to $21.00 from $20.00 while maintaining its prior rating. BTIG raised its price objective to $22.00 from $21.00, pointing to strong growth in the company’s Minimal Residual Disease (MRD) business, which grew 54% year-over-year in the fourth quarter and 46% for the full year. Piper Sandler reiterated an Overweight rating and projected clonoSEQ volume growth exceeding 30% alongside expanding margins.
Collectively, these analyst moves and the reported operational metrics were cited as evidence of Adaptive Biotechnologies’ strengthened position in the MRD market for hematological malignancies.
Context for market participants
The Form 4 filing provides a snapshot of an insider sale occurring against a backdrop of stronger-than-expected quarterly results and modest analyst target increases. The juxtaposition of an insider disposition with rising analyst targets and robust MRD growth figures may be of interest to investors monitoring insider activity, equity valuations, and revenue momentum in the biotech and diagnostics sectors.